Half-Year 2022 Financial and Clinical Trials Update
HY 2022: Core EPS development
Strong EPS development driven by growth in operations and accretion effect
Roche
CHF
10.66
+11.0%
+6.1 p
-1.5p
+2.9 p
+3.5 p
HY 2021
Operations¹
Ultomiris
patent settlement²
Net accretion
Novartis share
repurchase³
11.83
4
Other
HY 2022
At Constant Exchange Rates (CER); 1 Core operating profit excluding impacts from Ultomiris patent settlement, 2 Net impact from the Ultomiris patent settlement: gross income net of income tax and non-
controlling interests, 3 Impact of lower number of shares partially offset by increase in interest expense, 4 Other (net) include effects from changes in financial income/expenses (incl.
gains/losses on equity securities), changes in effective tax rate and changes in non controlling interests
54View entire presentation